ORIGINAL_ARTICLE
Genetic polymorphism of N142D GSTO2 and susceptibility to breast cancer: a meta-analysis
To establish a comprehensive picture of the relationship between glutathione S-transferase omega 2 (GSTO2; MIM: 612314) gene N142D variant (rs. 156697) and breast cancer risk, the present meta-analysis was carried out. Studies published up to July 2012 with information about GSTO2 polymorphism and breast cancer risk were identified using several electronic databases. We identified 4 eligible studies, including 2678 subjects (1316 patients, and 1362 healthy controls) in relation to the N142D polymorphism of GSTO2 and risk of breast cancer. There was no heterogeneity between studies. Considering all of the studies, the DD (OR=1.29, 95%CI: 0.99-1.67, P=0.055) and ND (OR=1.03, 95%CI: 0.88-1.21, P=0.697) genotypes, did not alter the risk of breast cancer in comparison with the NN genotype. Therefore, it is suggested that if the number of studies increased, finding a significant association between N142D polymorphism of GSTO2 and susceptibility to breast cancer would be very probable.
https://mbrc.shirazu.ac.ir/article_239_b5cf7bf33b97ce4921ba5d391959a448.pdf
2012-09-01
39
44
10.22099/mbrc.2012.239
Breast cancer
Meta-analysis
GSTO2
Susceptibility
Mostafa
Saadat
msaadat41@yahoo.com
1
Shiraz University
LEAD_AUTHOR
1. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. Characterization of the human omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 2003;13:131-144.
1
2. Mukherjee B, Salavaggione OE, Pelleymounter LL, Moon I, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos 2006;34:1237-1246.
2
3. Masoudi M, Saadat M. Arsenic, GSTO2 Asp142Asp polymorphism, health and treatment. EXCLI Journal 2008;7:115-118.
3
4. Masoudi M, Saadat I, Omidvari S, Saadat M. Association between N142D genetic polymorphism of GSTO2 and susceptibility to colorectal cancer. Mol Biol Rep 2011;38:4309-4313.
4
5. Pongstaporn W, Pakakasama S, Sanguansin S, Hongeng S, Petmitr S. Polymorphism of glutathione S-transferase Omega gene: association with risk of childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2009;135:673-678.
5
6. Wang YH, Yeh SD, Shen KH, Shen CH, Juang GD, Hsu LI, Chiou HY, Chen CJ. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol 2009; 241:111-118.
6
7. Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 2006;132:521-528.
7
8. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett 2006;236:276-281.
8
9. Chariyalertsak S, Purisa W, Sangrajrang S. Role of glutathione S-transferase omega gene polymorphisms in breast-cancer risk. Tumori 2009;95:739-743.
9
10. Masoudi M, Saadat I, Omidvari S, Saadat M. Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer. Breast Cancer Res Treat 2010;120:263-265.
10
11. Andonova IE, Justenhoven C, Winter S, Hamann U, Baisch C, Rabstein S, Spickenheuer A, Harth V, Pesch B, Brüning T, Ko YD, Ganev V, Brauch H. No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk. Breast Cancer Res Treat 2010;121:497-502.
11
12. Richard F, Pacyna-Gengelbach M, Schlüns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I, Schwendel A. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 2000;89:305-310.
12
13. Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000;60: 4519-4525.
13
14. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol 2001; 158:207-214.
14
15. Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S. Molecular alterations in columnar cell lesions of the breast. Mod Pathol 2006;19:344-349.
15
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188.
16
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
17
18. Masoudi M, Saadat I, Omidvari S, Saadat M. Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer. Breast Cancer Res Treat 2010;120:263-265.
18
19. Saadat M, Ansari-Lari M. Genetic polymorphism of glutathione S-transferase T1, M1 and asthma, a meta-analysis of the literature. Pak J Biol Sci 2007;10:4183-4189.
19
20. Saadat M. Apolipoprotein E (APOE) polymorphisms and susceptibility tobreast cancer: A meta-analysis. Cancer Res Treat 2012;44:121-126.
20
21. Saadat M. Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci 2006;97:505-509.
21
22. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006;54:267-283.
22
23. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005;14:1810-1818.
23
24. Saadat I, Saadat M. Glutathione S-transferase M1 and T1 null genotypes and the risk of gastric and colorectal cancers. Cancer Lett 2001;169:21-26.
24
25. Saadat M, Saadat I, Saboori Z, Emad A. Combination of CC16, GSTM1, and GSTT1 genetic polymorphisms is associated with asthma. J Allergy Clin Immunol 2004;113:996-998.
25
26. Mohammadynejad P, Saadat I, Ghanizadeh A, Saadat M. Bipolar disorder and polymorphisms of glutathione S-transferases M1 (GSTM1) and T1 (GSTT1). Psychiatry Res 2011;186:144-146.
26
ORIGINAL_ARTICLE
A novel low molecular weight extracellular protease from a moderately halophilic bacterium Salinivibrio sp. strain MS-7: production and biochemical properties
Kinetics of bacterial growth and protease production were monitored on a novel isolated moderately halophilic bacterium, Salinivibrio sp. strain MS-7, and maximum growth and protease activity was achieved after 48 hours at 30°C and 180 rpm. To determine the effect of various carbon sources on protease production, glucose, lactose, sucrose and maltose were investigated and maximum production of the enzyme was obtained in a basal medium (pH 8.0) containing maltose as a carbon source (494 U/ml). The protease was isolated from a stationary phase culture, purified 3.6-fold with 56% yield by a simple procedure and characterized biochemically. The enzyme revealed a monomeric structure with a relative molecular mass of 21 KDa by running on SDS-PAGE. Maximum caseinolytic activity of the enzyme was observed at 50°C, pH 8.0 and 0–0.5 M NaCl with a high tolerance to salt concentrations of up to 3 M. The effect of various metal ions and inhibitors on caseinolytic activity of the purified protease revealed that it probably belongs to the subclass of serine metalloproteases. These findings suggest that the protease secreted by Salinivibrio sp. strain MS-7 can be introduced as a candidate for biotechnological applications based on its haloalkaline properties.
https://mbrc.shirazu.ac.ir/article_576_34b441f5dc7a74149fb68ee85b92b201.pdf
2012-10-30
45
56
10.22099/mbrc.2012.576
Salinivibrio sp. strain MS-7
Biochemical properties
Low molecular weight protease
Moderately halophilic bacterium
Production optimization
Mahnaz
Shahbazi
mhz.shahbazi@gmail.com
1
Molecular Biotechnology Lab, Department of Biology, Faculty of Sciences, Shiraz University, Shiraz 71454, Iran
AUTHOR
Hamid Reza
Karbalaei-Heidari
karbalaei@shirazu.ac.ir
2
Molecular Biotechnology Lab, Department of Biology, Faculty of Sciences, Shiraz University, Shiraz 71454, Iran
LEAD_AUTHOR
Mala M, Srividya S. Partial purification and properties of a laundry detergent compatible alkaline protease from a newly isolated Bacillus species Y. Indian J Microbiol 2010;50: 309-317.
1
Gupta R, Beg QK, Lorenz P. Bacterial alkaline proteases: molecular approaches and industrial applications. Appl Microbiol Biotechnol 2002;59:15-32.
2
Rao MB, Tanksale AM, Ghatge MS, Deshpande VV. Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev 1998;62:597-635.
3
Hough DW, Danson MJ. Extremozymes. Curr Opin Chem Biol 1999;3:39-46.
4
Margesin R, Schinner F. Potential of halotolerant and halophilic microorganisms for biotechnology. Extremophiles 2001;5:73-83.
5
Van Den Burg B. Extremophiles as a source for novel enzymes. Curr Opin Microbiol 2003;6:213-218.
6
Mellado E, Sánchez-Porro C, Martín S, Ventosa A. Extracellular hydrolytic enzymes produced by moderately halophilic bacteria, Halophilic microorganisms. Springer, Berlin, 2004, pp. 285–295.
7
Sanchez-Porro C, Martin S, Mellado E, Ventosa A. Diversity of moderately halophilic bacteria producing extracellular hydrolytic enzymes. J Appl Microbiol 2003;94:295-300.
8
Mellado E, Moore ER, Nieto JJ, Ventosa A. Analysis of 16S rRNA gene sequences of Vibrio costicola strains: description of Salinivibrio costicola gen. nov., comb. nov. Int J Syst Bacteriol 1996;46:817-821.
9
Huang CY, Garcia JL, Patel BK, Cayol JL, Baresi L, Mah RA. Salinivibrio costicola subsp. vallismortis subsp. nov., a halotolerant facultative anaerobe from Death Valley, and emended description of Salinivibrio costicola. Int J Syst Evol Microbiol 2000;50:615-622.
10
Romano I, Gambacorta A, Lama L, Nicolaus B, Giordano A. Salinivibrio costicola subsp. alcaliphilus subsp. nov., a haloalkaliphilic aerobe from Campania Region (Italy). Syst Appl Microbiol 2005;28:34-42.
11
Amoozegar MA, Schumann P, Hajighasemi M, Fatemi AZ, Karbalaei-Heidari HR. Salinivibrio proteolyticus sp. nov., a moderately halophilic and proteolytic species from a hypersaline lake in Iran. Int J Syst Evol Microbiol 2008;58:1159-1163.
12
Chamroensaksri N, Tanasupawat S, Akaracharanya A, Visessanguan W, Kudo T, Itoh T. Salinivibrio siamensis sp. nov., from fermented fish (pla-ra) in Thailand. Int J Syst Evol Microbiol 2009;59:880-885.
13
Romano I, Orlando P, Gambacorta A, Nicolaus B, Dipasquale L, Pascual J, Giordano A, Lama L. Salinivibrio sharmensis sp. nov., a novel haloalkaliphilic bacterium from a saline lake in Ras Mohammed Park (Egypt). Extremophiles 2011;15:213-220.
14
Lama L, Romano I, Calandrelli V, Nicolaus B, Gambacorta A. Purification and characterization of a protease produced by an aerobic haloalkaliphilic species belonging to the Salinivibrio genus. Res Microbiol 2005;156:478-484.
15
Karbalaei-Heidari HR, Ziaee A-A, Schaller J, Amoozegar MA. Purification and characterization of an extracellular haloalkaline protease produced by the moderately halophilic bacterium, Salinivibrio sp. strain AF-2004. Enzyme Microb Technol 2007;40: 266-272.
16
.Karbalaei-Heidari HR, Ziaee AA, Amoozegar MA. Purification and biochemical characterization of a protease secreted by the Salinivibrio sp. strain AF-2004 and its behavior in organic solvents. Extremophiles 2007;11:237-243.
17
Smibert RM, Krieg NR. 1994. Phenotypic characterization, p. 615. In P. Gerhardt, R. Murray, W. Wood, and N. Krieg (ed.), Methods for general and molecular bacteriology. ASM Press, Washington, DC.
18
Ventosa A, Quesada E, Rodrı´guez-Valera F, Ruiz-Berraquero F, Ramos-Cormenzana A. (1982). Numerical taxonomy of moderately halophilic Gram-negative rods. J Gen Microbiol 128, 1959–1968.
19
Tamura K, Dudley. J, Neim M. MEGA 4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596–1599.
20
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
21
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
22
Chu WH. Optimization of extracellular alkaline protease production from species of Bacillus. J Ind Microbiol Biotechnol 2007;34:241-245.
23
Joo HS, Kumar CG, Park GC, Paik SR, Chang CS. Oxidant and SDS-stable alkaline protease from Bacillus clausii I-52: production and some properties. J Appl Microbiol 2003;95:267-272.
24
Sanchez-Porro C, Mellado E, Bertoldo C, Antranikian G, Ventosa A. Screening and characterization of the protease CP1 produced by the moderately halophilic bacterium Pseudoalteromonas sp. strain CP76. Extremophiles 2003;7:221-228.
25
Patel R, Dodia M, Singh SP. Extracellular alkaline protease from a newly isolated haloalkaliphilic Bacillus sp.: Production and optimization. Process Biochem 2005;40: 3569-3575.
26
Karbalaei-Heidari HR, Amoozegar MA, Hajighasemi M, Ziaee AA, Ventosa A. Production, optimization and purification of a novel extracellular protease from the moderately halophilic bacterium Halobacillus karajensis. J Ind Microbiol Biotechnol 2009;36:21-27.
27
Ningthoujam DS, Kshetri P, Sanasam S, Nimaichand S. Screening, identification of best producers and optimization of extracellular proteases from moderately halophilic alkalithermotolerant indigenous actinomycetes. World Appl Sci J 2009;7:907-916.
28
Akel H, Al-Quadan F, Yousef TK. Characterization of a purified thermostable protease from hyperthermophilic Bacillus strain HUTBS71. Eur J Sci Res 2009;31:280-288.
29
Dutta JR, Dutta PK, Baberjee R. Kinetic study of a low molecular weight protease from newly isolated Pseudomonas sp. using artificial neural network. Indian J Biotechnol 2005;4:127-133.
30
Ningthoujam DS, Kshetri P. A thermostable alkaline protease from a moderately halo-alkalithermotolerant Bacillus Subtilis strain SH1. Aus J Basic and Appl Sci 2010;4:5126-5134.
31
Deng A, Wu J, Zhang Y, Zhang G, Wen T. Purification and characterization of a surfactant-stable high-alkaline protease from Bacillus sp. B001. Bioresour Technol 2010; 101:7111-7117.
32
Jellouli K, Ghorbel-Bellaaj O, Ayed HB, Manni L, Agrebi R, Nasri M. Alkaline-protease from Bacillus licheniformis MP1: Purification, characterization and potential application as a detergent additive and for shrimp waste deproteinization. Process Biochem 2011;46: 1248-1256.
33
Setyorini E, Takenaka S, Murakami S, Aoki K. Purification and characterization of two novel halotolerant extracellular proteases from Bacillus subtilis strain FP-133. Biosci Biotechnol Biochem 2006;70:433-440.
34
ORIGINAL_ARTICLE
Nuclear factor-κB1 expression levels in human gastric adenocarcinoma
NF-κB pathway is a link between inflammation and cancer and is involved in cellular responses to different stimuli. Gastrointestinal lumen is exposed to many inflammatory agents such as foods, free radicals and bacterial or viral antigens. The aim of the present study was to evaluate the possible role of NF-κB1in gastric adenocarcinoma. To detect the relative level of NF-κB1transcript, total RNA was extracted from tissue specimens, a cDNA library was generated, and quantitative RT-PCR was performed for thirty human gastric adenocarcinoma tissue samples and thirty matched normal gastric tissue samples. NF-κB1 expression showed two-sidedness, which means that a group of 11 sample pairs showed up-regulation and a group of 16 sample pairs showed down-regulation. No histopathologic characteristics of samples could justify the observed two-sidedness. The NF-κB1 two-sidedness expression indicates the involvement of NF-κB1 and in a larger scale, NF-κB signaling pathway in gastric carcinogenesis. Our results show the complexity of regulatory mechanisms involved in developing and controlling the process of gastric cancer pathogenesis.
https://mbrc.shirazu.ac.ir/article_627_ec9aa963df4ab899949b75013c46c83d.pdf
2013-01-05
57
64
10.22099/mbrc.2013.627
Gastric cancer
NF-κB1
qRT-PCR
Gene expression
Razieh
Ebrahimi-Askari
: Behmanesh@modares.ac.ir
1
Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
AUTHOR
Mehrdad
Behmanesh
behmanesh@modares.ac.ir
2
Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
LEAD_AUTHOR
Maryam
Ghalandary
hmanesh@modares.ac.ir
3
Department of Genetics, School of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
AUTHOR
Masoud
Soleimani
ehmanesh@modares.ac.ir
4
2Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
AUTHOR
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: Epidemiology and risk factors. Arch Iran Med 2009;12:576-583.
1
Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006;12:2979-2990.
2
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand1965;64:31-49.
3
Raskatov JA, Meier JL, Puckett JW, Yang F, Ramakrishnan P, Dervan PB, Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci USA 2012;109:1023-1028.
4
Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med1999;5:412-417.
5
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPi etro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science1992;258:1798-1801.
6
Kang MR, Kim MS, Kim SS, Ahn CH, Yoo NJ Lee SH. NF-kappa B signaling proteins p50/p105, p52/p100 RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas. Pathology 2009;41:622-625.
7
Karst AM, Gao K, Nelson CC, Li G. Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 2009;124: 494–501.
8
Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
9
Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology 1977;113:1099-1109.
10
Kim H, Lim JW, Kim KH. Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor –kappa B. Scand J Gastroenterol 2001;36:706-716.
11
Pasparakis M. Regulation of tissue homeostasis by NF-kappa B signaling: implications for inflammatory disease. Nat Rev Immunol 2009;9:778-788.
12
Arora H, Qureshi R, Jin S, Park AK, Park WY. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NF-κB1. Exp Mol Med 2011;43: 298-304.
13
Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, Mertz KD,Gerstein M, Rubin MA. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 2007;67:10296-10303.
14
Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 2009;106:5282-5287.
15
Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer 2010;9:16.
16
ORIGINAL_ARTICLE
Molecular dynamics simulation and docking studies on the binding properties of several anticancer drugs to human serum albumin
Disposition and transportation of anticancer drugs by human serum albumin (HSA) affects their bioavailability, distribution and elimination. In this study, the interaction of a set of anticancer drugs with HSA was investigated by molecular dynamics and molecular docking simulations. The drugs' activities were analyzed according to their docking scores, binding sites and structural descriptors. The results displayed the ability of cavity 1, located in the cleft between domains I and III, to potentiate as the principal binding site of all tested drugs. This cavity provides a large space without any effective steric hindrance and induces the stability of the drugs in their binding sites by short and long ranged interactions with the accessible residues. Yet, specific structural features may lead some drug configurations to advance stronger interactions with cavities other than cavity 1. Also, the small volume and position of some cavities i.e. cavities 3, 5-10 involve penetration, small molecular volume and specific geometry which consequently force most drugs out of the corresponding binding sites. Therefore, the steric factor seems to play the most important role in the transportation of drugs by HSA.
https://mbrc.shirazu.ac.ir/article_628_51277fb4268216f31896758766803921.pdf
2013-01-05
65
73
10.22099/mbrc.2013.628
Anticancer drugs
Human serum albumin
Molecular dynamics simulation
Molecular docking
Cavities
Fatemeh
Keshavarz
F.Keshavarz@sutech.ac.ir
1
Department of Chemistry, Shiraz University of Technology, Shiraz 71555-313, Iran
AUTHOR
Mohammad Mehdi
Alavianmehr
papari@chem.susc.ac.ir
2
Department of Chemistry, Shiraz University of Technology, Shiraz 71555-313, Iran.
AUTHOR
Reza
Yousefi
ryousefi@shirazu.ac.ir
3
Protein Chemistry Laboratory (PCL), Department of Biology, Shiraz University, Shiraz 71454, Iran.
LEAD_AUTHOR
Li Y, He WY, Liu H, Yao X, Hu Z. Daidzein interaction with human serum albumin studied using optical spectroscopy and molecular modeling methods. J Mol Struc 2007; 831:144-150.
1
Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH. Ligand binding strategies of human serum albumin: How can the cargo be utilized? Chirality 2010;22: 77-87.
2
Falé PLV, Ascensão L, Serralheiro MLM, Haris PI. Interaction between Plectranthus barbatus herbal tea components and human serum albumin and lysozyme: Binding andactivity studies. Spectroscopy 2011;26:79-92.
3
Abu-Surrah AS, Kettunen M. Platinum Group Antitumor Chemistry: Design and development of New Anticancer Drugs Complementary to Cis-platin. Cur Med Chem 2006; 13:1337-1357.
4
Cohen S, Margalit R. Binding of porphyrin to human serum albumin: Structure-activity relationships. J Biochem 1990;270:325-330.
5
Dezhampanah H, Bordbar AK, Farshad S. Thermodynamic characterization of phthalocyanine–human serum albumin interaction. Spectroscopy 2011;25:235-242.
6
He X M, Carter DC. Atomic structure and Chemistry of human serum albumin. Nature 1992; 358:209-215.
7
Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976;12:1052-1061.
8
Sjoholm I, Ekman B, Kober A, Ljungstedt-Pahlman I, Seiving B, Sjodin T. Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 1979;16:767-777.
9
Tian J, Liu J, Xie J, Yao X, Hu Z, Chen X. Binding of wogonin to human serum albumin: a common binding site of wogonin in subdomain IIA. J Photochem Photobio B: Bio 2004;74: 39-45.
10
Radin NS. Meta-analysis of anticancer drug structures - significance of their polar allylic moieties, anti-cancer agents in medicinal chemistry. Anti-Cancer Agents 2007;7:209-222.
11
Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto RNS, Koga T, Sueyasu M, Egashira N, Inoshima I, Nakanishi Y, Oishi R. Protection against the extravasation of anticancer drugs by standardization of the management system. Hos Pharm 2008;43:571-576.
12
Yi-Lwern Yap K, Kuo EY, Jun Jie Lee J, Chui WK, Chan A. An onco informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Supp Care in Cancer 2010;18:883-891.
13
Hurria L, Balducci A. Geriatric Oncology, in: B.S. Mohile S, Nagovskiy N, Balducci L (Eds.), Chemotherapy for the older adult with cancer. Springer USA 2009; pp:201-261.
14
Newman DJ, Cragg GM. The discovery of anticancer drugs from natural sources. Nat Products 2005;3:129-168.
15
HyperChem, Release 7.0 for windows, Hypercube, Inc., 2002.
16
Berendsen HJC, van der Spoel D, van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 1995;91:43-56.
17
Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001;7:306-317.
18
van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible and free. J Comput Chem 2005;26:1701-1719.
19
Ghuman, J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353:38.
20
van Gunsteren WF, Billeter SR, Eising AA, Huenberger PH, Kruger P, Mark AE, Scott WRP, Tironi IG. Biomolecular simulation: the GROMOS 96 manual and user guide; Switzerland: 1996.
21
Darden T, York D, Pedersen L. Particle mesh Ewald-an NlogN method for Ewald sums in large systems. J Chem Phys 1993;98:10089-10092.
22
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys 1995;103:8577-8593.
23
Kennard EH, Earle HK. Kinetic theory of gases: with an introduction to statistical mechanics. McGraw-Hill, New York; 1938.
24
Huang K. Statistical mechanics. Wiley, New York; 1963.
25
Swope WC, Andersen HC, Berens PH, Wilson KR. A computer simulation method for the calculation of equilibrium constants for the formation of physical clusters of molecules: application to small water clusters. J Chem Phys 1982;76:637-649.
26
Berendsen HJC, Postma JPM, Van Gunstetren WF, Hermans J. Interaction models for water in relation to protein hydration. In: Pullman B (ed) Intermolecular forces. Reidel, Dordrecht, Netherlands, 1981;331-342.
27
Andersen HC. Molecular dynamics simulations at constant pressure and/or temperature. J Chem Phys 1980;72:2384-2393.
28
Berendsen HJC, Postma JPM, Van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
29
Van Gunsteren WF, Berendsen HJC. A leap-frog algorithm for stochastic dynamics. Mol Sim 1988;1:173-185.
30
Thomsen R, Christensen MH. MolDock: A new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315-3321.
31
www.talete.mi.it
32
Ilab.acdlabs.com/iLab2/
33
He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992;358:209-215.
34
Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites, Nature Struct Biol 1998;5:827-835.
35
Curry S, Brick P, Franks NP. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta 1999;1441:131.
36
Petitpas I, Bhattacharya AA, Twine S, East M, Curry S. Crystal structure analysis of warfarin binding to human serum albumin. J Biol Chem 2001;276:22804.
37
ORIGINAL_ARTICLE
Effect of vanillin and its acid and alcohol derivatives on the diphenolase activity of mushroom tyrosinase
For the first time in the present study the effects of vanillin, vanillyl alcohol, vanillic acid, as well as the newly synthesized vanillin derivative, bis-vanillin, were investigated on the oxidation of dopamine hydrochloride by mushroom tyrosinase. Among them, vanillin and bis-vanillin act as activators, while vanillyl alcohol and vanillic acid exhibited inhibitory effects, the IC50 values being estimated 1.5 and 1.0 mM, respectively. These compounds were mixed inhibitors. The presence of aldehyde and metoxy groups at the meta position of aromatic compounds seems to cause them to react as tyrosinase activators, as observed in the case of vanillin and bis-vanillin. The presence of both groups in bis-vanillin results in a stronger activation effect compared to vanillin. The results indicate that the electron-withdrawing capacity of the functional group at the C-1 position is essential for the inhibitory potency of vanillin derivatives. In comparison with other benzoic acid derivatives, the results obtained in this study suggest that the relative positioning of hydroxy and methoxy groups at meta and para positions plays an important role in the inhibition effects of benzoic acids and their inhibition potency.
https://mbrc.shirazu.ac.ir/article_630_76a32ee12ccf3f1232039c957bd2a28b.pdf
2013-01-15
74
82
10.22099/mbrc.2013.630
Tyrosinase
Inhibition
Enzymatic browning
Vanillin
Masoomeh
Bagheri-Kalmarzi
e.m_bagheri20@yahoo.com
1
Department of Biology, Faculty of Science, Payame Noor University, Tehran, Iran
AUTHOR
Reza
H.Sajedi
sajedi_r@modares.ac.ir
2
Department of Biochemistry, Faculty of Biologilal Sciences, Tarbiat Modares University, Tehran, Iran
LEAD_AUTHOR
Elham
Asadollahi
sajedi_r@yahoo.com
3
Department of Chemistry, Faculty of Sciences, University of Guilan, Rasht, Iran
AUTHOR
Nosrat
Mahmoodi
nosmahmoodi@gmail.com
4
Department of Chemistry, Faculty of Sciences, University of Guilan, Rasht, Iran
AUTHOR
Reza
Haji-Hosseini
hosseini@pnu.ac.ir
5
Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
AUTHOR
1. Prota G. Progress in the chemistry of melanins and related metabolites. Med Res Rev 1988;8:525-556.
1
2. Mayer AM. Polyphenol oxidases in plants and fungi: Going places? A review. Phytochemistry 2006;67:2318-2331.
2
3. Sánchez-Ferrer A, Rodríguez-López JN, García-Cánovas F, García-Carmona F. Tyrosinase: A comprehesive review of its mechanism. Biochim Biophys Acta 1995;1247:1-11.
3
4. Friedman M. Food browning and its prevention: An overview. J Agric Food Chem 1996;44:631-653.
4
5. Kubo I, Kinst-Hori I. Tyrosinase inhibitors from cumin. J Agric Food Chem 1998;46:5338-5341.
5
6. Kramer KJ,HopkinsTL. Tyrosinase metabolism for insect cuticle tanning. Arch Insect Biochem Physiol 1987;6:279-301.
6
7. Christensen BM, Li J, Chen C, Nappi AJ. Melanization immune responses in mosquito vectors. Trends Parasitol 2005;21:192-199.
7
8. Boss PK,GardnerRC, Janssen B, Ross GS. An apple polyphenol oxidase cDNA is up-regulated in wounded tissues. Plant Mol Biol 1995;27:429-433.
8
9. Ensminger AH, Ensminger ME, Konlande JE, Robson JRK. CRC Press.Boca Raton,LA1995.
9
10. Viterbo A, Yagen B, Mayer AM. Cucurbitacins, ‘attack’ enzymes and laccase in Botrytis cinerea. Phytochemistry 1992;32:61-65.
10
11. Pifferi PG, Baldassari L, Cultrera R. Inhibition by carboxylic acids of an o-diphenol oxidase from Prunus avium fruits. J Sci Food Agric 1974;25:263-270.
11
12. Maeda K, Fukuda M. In vitro effectiveness of several whitening cosmetic compounds in human melanocytes. J Soc Cosmet Chem 1991;42:361-368.
12
13. Huang XH, Chen QX, Wang Q, Song KK, Wang J, Sha L, Guan X. Inhibition of the activity of mushroom tyrosinase by alkylbenzoic acids. Food Chem 2006;94:1-6.
13
14. Jun N, Hong G, Jun K. Synthesis and evalution of 2',4',6'-trihydroxychalcones as a new class of tyrosine inhibitors. Bioorg Med Chem 2007;15:2396-2402.
14
15. Xie JJ, Song KK, Qiu L, He Q, Huang H, Chen QX. Inhibitory effects of substrate analogues on enzyme activity and substrate specificities of mushroom tyrosinase. Food Chem 2007;103:1075-1079.
15
16. McEvily AJ, Iyengar R, Gross A. Inhibition of enzymatic browning in foods and beverages. U S patent 1991;32:253-273.
16
17. Rescigno A, Sollai F, Pisu B, Rinaldi A, Sanjust E. Tyrosinase inhibition: general and applied aspects. J Enzym Inhib Med Chem 2002;17:207-218.
17
18. Noh JM, Kwak SY, Seo HS, Seo JH, Kim BG, Lee YS. Kojic acid-amino acid conjugates as tyrosinase inhibitors. Bioorg Med Chem Lett 2009;19:5586-5589.
18
19. Kubo I, Kinst-Hori I, Kubo Y, Yamagiwa Y, Kamikawa T, Haraguchi H. Molecular design of antibrowning agents. J Agric Food Chem 2000;48:1393-1399.
19
20. Bradford MM. A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
20
21. Robb DA. Tyrosinase. In: Lontie R (ed.) Copper proteins and copper enzymes, CRC Press. Boca Raton, FL, 1984; pp 207-240.
21
22. Zhang JP, Chen QX, Song KK, Xie JJ. Inhibitory effects of salicylic acid family compounds on the diphenolase activity of mushroom tyrosinase. Food Chem 2006; 95:579-584.
22
23. Copeland RA. Enzymes. Wiley-VCH, USA. 2000.
23
24. Akhtar M. SUSB-039, Suny Stony Brook, CHE 133Rev 12/06. 2008.
24
25. Irwin AP. Organic Syntheses. CV 4, 927. 1963.
25
26. Delomenede M, Bedos-Belval F, Duran H, Vindis C, Baltas M, Negre-Salvayre A. Development of novel antiatherogenic biaryls: design, synthesis, and reactivity. J Med Chem 2008;51:3171-3181.
26
27. Robit C, Rouch C, Cadet F. Inhibition of palmito (Axanthophoenix rubra) polyphenol oxidase by carboxylic acids. Food Chem 1997;59:355-360.
27
28. Kahn V, Ben-Shalom N. Zakin V. Effect of kojic acid on the oxidation of N-acetyldopamine by mushroom tyrosinase. J Agric and Food Chem. 1997;45:4460-4465.
28
29. Gao H, Nishida J, Saito SH, Kawabata J. Inhibitory effects of 5,6,7-trihydroxyflavones on tyrosinase. Molecules 2007;12:86-97.
29
30. Nerya O, Musa R, Khatib S, Tamir S, Vaya J. Chalcones as potent tyrosinase inhibitors: the effect of hydroxyl positions and numbers. Phytochemistry. 2004;65:1389-1395.
30
31. Chen QX, Song KK, Qiu L, Liu XD, Huang H, Guo HY (2005) Inhibitory effects on mushroom tyrosinase by ρ-alkoxybenzoic acids. Food Chem 91:269-274
31
32. Chen QX, Song KK, Qiu L, Liu XD, Huang H, Guo HY. Inhibitory effects on mushroom tyrosinase by ρ-alkoxybenzoic acids. Food Chem 2005;91:269-274.
32
33. Likhitwitayawuid K. Stilbenes with tyrosinase inhibitory activity 2008:94:44-52.
33
34. Shimizu K, Kondo R, Sakai K. Inhibition of tyrosinase by flavonoids, stilbenes and related 4-substituted resorcinols: structure-activity investigations. Planta Med 2000;66:11-15.
34
35. Kubo I, Chen QX, Nihei KI, Calderon JS, Cespedes CL. Tyrosinase inhibition kinetics of anisic acid. Z Naturforsch C 2003;58:713-718
35
ORIGINAL_ARTICLE
Molecular study of a consanguineous family with autosomal recessive mental retardation and speech disorder
Mental retardation (MR) is one of the most frequently found major genetic disorders around the world, affecting 1-3% of the people in the general population. The recent advancement in molecular biology and cytogenetic study has made possible the identification of new genes for a variety of genetic disorders including autosomal recessive MR. Recessive genetic disorders are common in Pakistan due to the high rate of consanguinity. A central focus of the present study was to map and identify the disease causing gene in a mentally retarded consanguineous Pakistani family with speech disorder. The study comprises of 20 individuals including 10 patients. Genetic analysis of autosomal recessive MR and speech disorders was carried out for eight known fundamental loci sorted out on the basis of clinical features. These loci including 3p26.2, 3p21.3, 7q22, 8p22, 11p15, 14q11.2-q12, 19p13.12, and 22p13 were screened using polymorphic microsatellite markers. To identify the disease locus, genomic DNA from each individual was genotyped for homozygosity analysis. Microsatellite markers were amplified using PCR. The study provided valuable data to exclude linkage of the above mentioned loci. The absence of any linkage of the Pakistani family with autosomal recessive MR to the eight well known loci, confirms the genetic heterogeneity of MR. These results need to be verified and the candidate gene be found by a complete genome scan, which may help us in establishing the genotype-phenotype correlation of MR, improving genetic counseling, carrier screening, DNAbased prenatal diagnosis and the opportunity to develop appropriate animal models to test new forms of cell or gene therapies.
https://mbrc.shirazu.ac.ir/article_1098_57cee48c0ee9da2b4b59496b01369a9f.pdf
2013-02-23
83
93
10.22099/mbrc.2013.1098
Mental retardation
Linkage analysis
Consanguineous Pakistani family
Syed Farhan
Ahmad
zaid_khan68@yahoo.com
1
Faculty of Basic and Applied Sciences, Department of Biotechnology and Bioinformatics, Islamic International University, New Campus, Sector H-10 Islamabad, Pakistan
LEAD_AUTHOR
Abdul
Hameed
ahameed0786@hotmail.com
2
Institute of Biomedical and Genetic Engineering KRL Islamabad, Pakistan
AUTHOR
Maryam
Jehangir
farhan.msbio88@gmail.com
3
Department of Bioinformatics, Shaheed Benazir Bhutto Woman University, Peshawer, Pakistan
AUTHOR
Jabar Zaman Khan
Khttak
jabar.khattak@iiu.edu.pk
4
Faculty of Basic and Applied Sciences, Department of Biotechnology and Bioinformatics, Islamic International University, New Campus, Sector H-10 Islamabad, Pakistan
AUTHOR
1. Ropers HH. X-linked mental retardation: many genes for a complex disorder, Curr Opin Genet Dev 2006;16:260-269.
1
2. Al-Ansari A. Etiology of mild mental retardation among Bahraini children: a community-based case control study. Ment Retard 1993;31:140-143.
2
3. Rauch A. Hoyer J, Guth S et al., Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation Am J Med Genet A 2006;140:2063-2074.
3
4. McLaren J, Bryson SE. Review of recent epidemiological studies of mental retardation: prevalence, associated disorders, and etiology. Am J Ment Retard 1987:92:243-254.
4
5. Bennett RL, Steinhaus KA, Uhrich SB, et al, Recommendations for standardized human pedigree nomenclature. J Gene Counsel 1995:4:267-279.
5
6. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a laboratory manual, 2nd ed. N.Y., Cold Spring Harbor Laboratory Press, 1995; p.1659.
6
7. Sayed HS, Aiysha A, Saba S, Shagufta K. Identification of LIPH gene mutation in a consanguineous family segregating the woolly hair/hypotrichosis phenotype. J Pak Med Assoc. 2011;61:1060-1064.
7
8. Kryndushkin DS, Alexandrov IM, Ter-Avanesyan MD, Kushnirov VV. Yeast [PSI+] prion aggregates are formed by small Sup35 polymers fragmented. J Biol Chem 2003;278:49636-4943.
8
9. http://www.ecomii.com/science/encyclopedia/human-genetics
9
10. http://www.ncbi.nlm.nih.gov/books/NBK21106
10
11. Roeleveld N, Zielhuis GA, Gabreels F. The prevalence of mental retardation: a critical review of recent literature. Dev Med Child Neurol 1997;39:125-132.
11
12. Leonard H, Wen X. The epidemiology of mental retardation: Challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 2002;8:117-134.
12
13. Ropers HH, Hamel BC. X-linked mental retardation. Nat Rev Genet 2005;6:46–57.
13
14. Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic intellectual disability: A review. J Neurodev Disord 2010;2:182-209.
14
15. Lencz T, Lambert C, DeRosse P, et al. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci USA 2007;104:19942-19947.
15
16. Najmabadi H, Motazacker MM, Garshasbi M, Kahrizi K, Tzschach A, Chen W, Behjati F, Hadavi V, Nieh SE, Abedini SS, Vazifehmand R, Firouzabadi SG, and 9 others., Homozygosity mapping in consanguineous families reveals extreme heterogeneity of non-syndromic autosomal recessive mental retardation and identifies 8 novel gene loci. Hum Genet 2007;121:43-48.
16
17. Rehman S, Baig SM, Eiberg H, Rehman S, Ahmad I, Malik NA, Tommerup N, Hansen L. Autozygosity mapping of a large consanguineous Pakistani family reveals a novel non-syndromic autosomal recessive mental retardation locus on 11p15-tel. Neurogenetics, 12, p. 247-251 Ropers H.H And Hamel B.C., (2005) X-linked mental retardation, Nat Rev Genet, 2011;6:46–57.
17
18. Jamra RA, Wohlfart S, Zweier M, Uebe S, Priebe L, Ekici A, Giesebrecht S, Abboud A, Al Khateeb MA, Fakher M, Hamdan S, Ismael A, Muhammad S, Nothen MM, Schumacher J, Reis A. Homozygosity mapping in 64 Syrian consanguineous families with non-specific intellectual disability reveals 11 novel loci and high heterogeneity. Eur J Hum Genet 2011;19:1161-1166.
18
19. Basel-Vanagaite L, Alkelai A, Straussberg R, Magal N, Inbar D, Mahajna M, Shohat M. Mapping of a new locus for autosomal recessive non-syndromic mental retardation in the chromosomal region 19p13.12-p13.2: further genetic heterogeneity. J Med Genet 2003;40:729-732.
19
20. Basel-Vanagaite L, Attia R, Yahav M, et al. The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation. J Med Genet 2006;43:203–210.
20
21. Ritvo ER, Mason-Brothers A, Menkes JH, Sparkes RS. Association of autism, retinoblastoma, and reduced esterase D activity. Arch Gen Psychiatry 1988;45:600.
21
22. Steele MM, Al-Adeimi M, Siu VM, Fan YS. A case of autism with interstitial deletion of chromosome 13. J Autism Dev Disord 2011;31:231-234.
22
23. Bradford Y, Haines J, Hutcheson H, Gardiner M, Braun T, Sheffield V, Cassavant T, Huang W, Wang K, Vieland V, Folstein S, Santangelo S, Piven J. Incorporating language phenotypes strengthens evidence of linkage to autism. Am J Med Genet 2001;105:539-547.
23